• Explore /
  • Poster
  • / A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).

A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).

Abstract Poster

Authors

null

Kentaro Yamazaki

Divison of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan

Kentaro Yamazaki , Michitaka Nagase , Hiroshi Tamagawa , Shinya Ueda , Takao Tamura , Kohei Murata , Takashi Tsuda , Eishi Baba , Masahiro Tsuda , Toshikazu Moriwaki , Taito Esaki , Yasushi Tsuji , Kei Muro , Koichi Taira , Tadamichi Denda , Takahiro Tsushima , Masahiko Ando , Satoshi Morita , Narikazu Boku , Ichinosuke Hyodo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

UMIN000001396

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3534)

DOI

10.1200/jco.2014.32.15_suppl.3534

Abstract #

3534

Poster Bd #

23

Abstract Disclosures

Similar Posters

First Author: Kathrin Heinrich

First Author: Yuki Matsubara

First Author: Zev A. Wainberg

First Author: Sotaro Sadahiro